You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK)2022年歸母淨利潤升10.0%至41.47億港元 創新轉型推動業績穩健增長
格隆匯 03-30 12:30

格隆匯3月30日丨華潤醫藥(03320.HK)公佈2022年度業績,報吿期間內,集團積極應對市場和行業變化,加快創新轉型推動業績穩健增長,錄得總收益達2541.06億港元,較2021年總收益2368.06億港元增長7.3%(以人民幣口徑增長10.8%)。2022年製藥、醫藥分銷、藥品零售三個主要業務分部的收益佔比分別為15.8%、80.7%以及3.5%。

報吿期間內集團實現毛利391.35億港元,較2021年的毛利353.80億港元增長10.6%(以人民幣口徑增長14.2%);整體毛利率為15.4%,與2021年毛利率14.9%相比提高0.5個百分點,主要因為報吿期間內毛利率水準較高的製藥業務收入佔比提升。

2022年,集團實現淨利潤78.43億港元,較2021年的淨利潤66.47億港元增長18.0%(以人民幣口徑增長20.4%)。集團實現公司擁有人應占溢利41.47億港元,較2021年公司擁有人應占溢利37.69億港元增長10.0%(以人民幣口徑增長11.7%);每股基本盈利為0.66港元,宣派末期股息每股0.16港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account